Cargando...
Thyroid dysfunction from inhibitor of fibroblast growth factor receptor
BACKGROUND: Thyroid dysfunction has not been previously reported in clinical trials of selective fibroblast growth factor receptor (FGFR) inhibitors including AZD4547. Herein, we report a case of worsening hypothyroidism in a patient with advanced urothelial cancer treated with AZD4547. CASE PRESENT...
Gardado en:
| Publicado en: | Exp Hematol Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6379924/ https://ncbi.nlm.nih.gov/pubmed/30820365 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-019-0130-4 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|